ALTEOGEN Inc (KQ:196170) — Market Cap & Net Worth
Market Cap & Net Worth: ALTEOGEN Inc (196170)
ALTEOGEN Inc (KQ:196170) has a market capitalization of $13.36 Billion (₩19.71 Trillion) as of May 3, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #1772 globally and #43 in its home market, demonstrating a 2.50% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ALTEOGEN Inc's stock price ₩368500.00 by its total outstanding shares 53482080 (53.48 Million). Analyse ALTEOGEN Inc operating cash flow efficiency to see how efficiently the company converts income to cash.
ALTEOGEN Inc Market Cap History: 2015 to 2026
ALTEOGEN Inc's market capitalization history from 2015 to 2026. Data shows growth from $199.85 Million to $13.36 Billion (53.59% CAGR).
Index Memberships
ALTEOGEN Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$299.07 Billion | 4.47% | #2 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$299.07 Billion | 4.47% | #2 of 1384 |
Weight: ALTEOGEN Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ALTEOGEN Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ALTEOGEN Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.11x
ALTEOGEN Inc's market cap is 0.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.18x
ALTEOGEN Inc's market cap is 0.18 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $199.85 Million | $4.73 Billion | $1.21 Billion | 0.04x | 0.17x |
| 2016 | $164.86 Million | $6.84 Billion | -$3.59 Billion | 0.02x | N/A |
| 2017 | $223.50 Million | $12.10 Billion | -$7.45 Billion | 0.02x | N/A |
| 2018 | $287.94 Million | $13.70 Billion | -$6.87 Billion | 0.02x | N/A |
| 2019 | $673.53 Million | $29.23 Billion | -$704.51 Million | 0.02x | N/A |
| 2020 | $3.62 Billion | $42.43 Billion | -$969.60 Million | 0.09x | N/A |
| 2021 | $2.29 Billion | $41.12 Billion | $6.00 Billion | 0.06x | 0.38x |
| 2022 | $1.39 Billion | $28.81 Billion | -$8.15 Billion | 0.05x | N/A |
| 2023 | $3.57 Billion | $96.52 Billion | -$3.37 Billion | 0.04x | N/A |
| 2024 | $11.22 Billion | $102.85 Billion | $62.25 Billion | 0.11x | 0.18x |
Competitor Companies of 196170 by Market Capitalization
Companies near ALTEOGEN Inc in the global market cap rankings as of May 3, 2026.
Key companies related to ALTEOGEN Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
ALTEOGEN Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, ALTEOGEN Inc's market cap moved from $199.85 Million to $ 13.36 Billion, with a yearly change of 53.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩13.36 Billion | -18.02% |
| 2025 | ₩16.29 Billion | +45.23% |
| 2024 | ₩11.22 Billion | +214.21% |
| 2023 | ₩3.57 Billion | +157.52% |
| 2022 | ₩1.39 Billion | -39.37% |
| 2021 | ₩2.29 Billion | -36.81% |
| 2020 | ₩3.62 Billion | +437.22% |
| 2019 | ₩673.53 Million | +133.92% |
| 2018 | ₩287.94 Million | +28.83% |
| 2017 | ₩223.50 Million | +35.57% |
| 2016 | ₩164.86 Million | -17.51% |
| 2015 | ₩199.85 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of ALTEOGEN Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.36 Billion USD |
| MoneyControl | $13.36 Billion USD |
| MarketWatch | $13.36 Billion USD |
| marketcap.company | $13.36 Billion USD |
| Reuters | $13.36 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ALTEOGEN Inc
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more